Which Name Brands Are Tirzepatide: Reading an Approval Record

By What Peptides Editorial Team · Updated 2026-09-14 · Part of Peptide Research, Industry Updates & Practical Guides

A brand name is a commercial designation attached to a specific marketing authorisation. It is not a chemical description and it is not a property of a molecule. Tirzepatide is the international nonproprietary name for a 39 residue peptide that acts at the glucose dependent insulinotropic polypeptide and the glucagon like peptide 1 receptors, and where it is approved it is a prescription medicine. A brand name is granted to one authorisation holder in one jurisdiction, so the same substance can carry different brand names in different markets. Which names exist is answered by a register rather than by a list.

This page reports on how such names are recorded and checked. It does not advise anyone on obtaining a medicine and it does not rank products. Three distinctions do the work: between the nonproprietary name and the brand, between an approved product and a generic, and between either of those and a compounded preparation. For the third distinction see what regulators have published on compounding, and for more reporting in this cluster see peptide research and industry updates. The procedure below is the same one a regulator or a pharmacist would apply.

Nonproprietary name, brand name, and what a register records

The international nonproprietary name is assigned through a World Health Organization programme and is intended to give one globally usable designation per active substance. A brand name is chosen by the authorisation holder and approved as part of the marketing authorisation, and it is protected as a trademark. A register entry therefore carries both: the nonproprietary name, which identifies the substance, and the brand, which identifies one specific product from one specific holder. A reader searching by brand will find one entry, while a reader searching by nonproprietary name will find every authorised product containing it.

Registers also record what the approval actually covers. An entry lists the marketing authorisation holder, the strength or strengths, the pharmaceutical form, the route of administration, the legal supply classification and the date of the authorisation. It lists the manufacturing sites. It may list a package description and a reimbursement category. What it does not list is any comparative view of products, and it does not list anything that has not been assessed. That completeness is the useful property: absence from the register is a fact rather than an omission.

Brand, generic, and compounded: three different statuses

An originator brand is the product that went through the full assessment, and its authorisation relies on the complete data package generated by its holder. A generic product is authorised through an abridged route once the period of data protection has expired; the applicant must demonstrate bioequivalence to the reference product, and the assessment addresses that comparison rather than the full evidence base. The nonproprietary name is shared by both. The same substance can therefore appear on a register several times, under different brand names, with different holders, and that is normal rather than suspicious.

A compounded preparation belongs to a third category. It is made under pharmacy practice for an individual, it holds no marketing authorisation, and no regulator has assessed it for safety, efficacy or equivalence. It cannot appear on an authorisation register, because a register lists authorisations. That is the point at which many listings become misleading: a product presented alongside an approved brand name may be a compounded preparation, and the register will simply not contain it. Regulators in several jurisdictions have published on that presentation, and the wording is consistent. See how other presentations are assessed for the same problem in another form.

• Search by nonproprietary name to see every authorised product, not only the one already known.
• Read the holder field, since a brand name identifies an authorisation rather than an entity.
• Compare the strength and form fields against what a listing claims to supply.
• Treat absence from the register as a finding rather than as an incomplete search.
• Confirm the supply classification, which sets how a product may lawfully reach a patient.

How to confirm a name in your own country

The procedure has four steps and takes a few minutes. First, identify the nonproprietary name of the substance, which is printed on any genuine label and in any regulator publication. Second, search the register maintained by the medicines regulator for your country, using the nonproprietary name rather than a brand, since brand names are local and the substance name travels. Third, open the entry and read the holder, the strengths, the form and the status. Fourth, where the register offers it, read the product information document, which carries the approved wording on what the product is authorised for.

Each jurisdiction keeps its own record. In the United States the Food and Drug Administration maintains the Orange Book of approved drug products with therapeutic equivalence evaluations, and DailyMed carries the manufacturer supplied label text. In the European Union, the European Medicines Agency publishes product information for centrally authorised products, while national regulators maintain their own registers for nationally authorised ones. Other countries maintain equivalent registers. Where a name cannot be found on any of them, the national regulator is the body to ask, and this site does not substitute for that answer. For the labelling vocabulary used on those registers see what the research use only label means and how supplement labelling categories are structured, since the same words appear on medicine and supplement labels with different meanings.

This page is part of the Peptide Research, Industry Updates & Practical Guides guide.